![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 25, 22111-22114, June 21, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Microbiology and Immunology, Pennsylvania
State University College of Medicine, Hershey, Pennsylvania 17033
Received for publication, March 14, 2002, and in revised form, May 2, 2002
Processing of the nf The NF- Another level of NF- The processing of wild type p100 can be induced by a noncanonical
NF- While it is clear that phosphorylation triggers the processing of p100,
the downstream molecular events involved in this signaling process
remain poorly defined. In this study, we have investigated the
mechanism of p100 ubiquitination and the role of this posttranslational modification in regulating p100 processing. Using the small interfering RNA (siRNA)-mediated gene suppression technique, we have demonstrated that Expression Vectors and Antibodies--
Expression vectors
encoding NIK and derivatives, p100 and derivatives, and HA-ubiquitin
have been described (15, 17). To construct the HA-tagged siRNA--
siRNA for human
Transfection of 293 cells was performed using LipofectAMINE 2000 (Invitrogen) following the manufacturer's instructions. Briefly, the
cells were seeded into six-well plates 12-16 h prior to transfection. About 0.6 nmol of the Immunoblotting (IB) and Coimmunoprecipitation (coIP)--
293
cells were transfected using DEAE-dextran (20) and lysed in RIPA buffer
supplemented with protease inhibitors (17). The cell lysates (about 7 µg) were subjected to SDS-PAGE and IB as described previously (21).
CoIP assays (using 250 µg of cell lysates) were performed as
described previously (15).
In Vivo Ubiquitin Conjugation Assays--
293 cells were
transfected in six-well plates with HA-ubiquitin and p100 together with
the indicated expression vectors. About 30 h posttransfection, the
cells were lysed in RIPA buffer and immediately subjected to IP using
anti-p100. The agarose beads were washed three times with RIPA buffer,
and the attached proteins were eluted in SDS loading buffer. The eluted
ubiquitin-conjugated p100 was analyzed by IB using horseradish
peroxidase-conjugated anti-HA.
With the RNAi genetic approach, we were also able to determine whether
NIK Induces the Binding of p100 to
Since NIK, but not NIK(K429A/K430A), is unable to induce p100
phosphorylation (15), we reasoned that the phosphorylation site of p100
might be required for Constitutive Processing of p100 Mutants Is Independent of
Processing of the nf Prior studies using a dominant-negative We have previously shown that p100 mutants lacking the C-terminal DD
undergo constitutive processing (15). Interestingly the processing of
these mutants is independent of We thank Dr. Warner Greene for reagents and
members of the Sun laboratory for discussion of the work.
*
This study was supported by United States Public
Health Service Grant 1R01 AI45045 (to S.-C. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Published, JBC Papers in Press, May 6, 2002, DOI 10.1074/jbc.C200151200
The abbreviations used are:
IKK, I
ACCELERATED PUBLICATION
Genetic Evidence for the Essential Role of
-Transducin
Repeat-containing Protein in the Inducible Processing of
NF-
B2/p100*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
b2
gene product p100 to generate p52 is an important step in
NF-
B regulation. This step is regulated by a nonclassical NF-
B
signaling pathway involving the NF-
B-inducing kinase (NIK). NIK
induces p100 processing by triggering phosphorylation of specific
C-terminal serines of p100. However, the downstream molecular
events leading to p100 processing remain unclear. Here we show that NIK
induced the physical recruitment of
-transducin repeat-containing
protein (
-TrCP), a component of the SCF ubiquitin ligase
complex, to p100. This event required the phosphorylation sites as well
as the death domain of p100. Using the RNA interference technique, we
demonstrated that
-TrCP is essential for NIK-induced p100
ubiquitination and processing. Interestingly the constitutive processing of p100 mutants was independent of
-TrCP. These results suggest that
-TrCP is an essential component of NIK-induced p100 processing.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
B family of transcription factors participates in the
regulation of diverse biological processes, including innate and
adaptive immune responses, lymphoid organ development and maturation,
inflammation, and cell growth and survival (1-4). Deregulated function
of NF-
B contributes to the development of various cell malignancies
(5, 6). Mammalian cells have five NF-
B proteins, RelA, RelB, c-Rel,
p50, and p52, which function as various homo- and heterodimers (7). In
most cell types, the NF-
B factors are sequestered in the cytoplasm
through physical interaction with specific ankyrin repeat-containing
inhibitors, including I
B
and homologues (8). The latent forms of
NF-
B can be activated by a large variety of chemical, environmental, and microbial agents, which act by inducing the phosphorylation and
subsequent degradation of I
B
(9, 10). This canonical NF-
B
signaling pathway depends on a multisubunit I
B kinase
(IKK),1 which is composed of
two catalytic subunits, IKK
and IKK
, and a regulatory subunit,
IKK
(also named NEMO, IKK
P1, or FIP-3) (11). When activated by
upstream signals, IKK directly catalyzes the phosphorylation of
I
B
at two specific serines, which in turn triggers its
ubiquitination. Recent biochemical studies suggest that the
-transducin repeat-containing protein (
-TrCP, also named
E3RSI
B) is involved in the ubiquitination of
phosphorylated I
B
, although genetic evidence is lacking (11).
B regulation is via processing of the NF-
B1
and NF-
B2 precursor proteins p105 and p100, a proteasome-mediated event required for generating p50 and p52, respectively (7, 12). Both
p105 and p100 contain ankyrin repeats at their C-terminal portions and
function as I
B-like NF-
B inhibitors by forming cytoplasmic
complexes with mature NF-
B subunits (13, 14). Thus, the processing
of p105 and p100 also serves to liberate the sequestered NF-
B
members. It seems clear that the processing of p105 is largely a
constitutive event (11), while the processing of p100 is tightly
controlled by both negative and positive regulatory mechanisms (15).
The C-terminal region of p100 contains a death domain (DD) that
functions as a processing-inhibitory domain (PID). Mutant forms of p100
lacking the PID undergo constitutive processing. Interestingly, in some
lymphoma cells, the nf
b2 gene is involved in
chromosomal translocations that produce C-terminal truncation mutants
of p100 lacking the PID, and at least some of these p100 mutants have
been shown to undergo constitutive processing (15). These findings
raise the possibility that deregulated processing of p100 may
contribute to the development of lymphoid malignancies.
B signaling pathway involving the NF-
B-inducing kinase (NIK)
(15). NIK induces p100 phosphorylation at specific C-terminal serines,
which serves as a trigger for its inducible processing. Consistently a
nik gene mutation in the alymphoplasia mice is associated with the absence of p100 processing, resulting in severe deficiencies in lymphoid organ development (15). More recent studies
suggest that NIK induces p100 phosphorylation through a downstream
kinase, IKK
(16). Interestingly IKK
is also involved in p100
processing induced by the retroviral oncoprotein Tax (17). In sharp
contrast, IKK
, which is essential for the canonical NF-
B
signaling, is completely dispensable for the inducible processing of
p100 (16, 17). These findings reveal a novel signaling pathway
specifically regulating the processing of p100, which is essential for
the development and maturation of lymphoid organs.
-TrCP is an essential component involved in NIK-induced ubiquitination of p100. In NIK-expressing cells,
-TrCP forms a
stable complex with p100 but not with a p100 mutant lacking its
phosphorylation site. We further demonstrate that
-TrCP-mediated p100 ubiquitination is essential for inducible, but not constitutive, processing of p100.
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-TrCP, the
-TrCP cDNA from Jurkat T cells was amplified by RT-PCR
and inserted into the pcDNA-HA vector (18). The
-TrCPiR is a mutant harboring sense mutations in the
siRNA targeting site that prevent the binding and degradation by the
specific siRNA. The anti-HA monoclonal antibody (horseradish
peroxidase-conjugated, 3F10) was purchased from Roche Molecular
Biochemicals. The antibody recognizing the N terminus of p100
(anti-p100) was kindly provided by Dr. W. C. Greene (19).
-TrCP and green fluorescent
protein (GFP) were synthesized by Dharmacon Research, Inc. (Lafayette,
CO). The sequences of
-TrCP siRNA are: GUG GAA UUU GUG GAA CAU CTT
(sense) and GAU GUU CCA CAA AUU CCA CTT (antisense). The sequences of GFP siRNA are: GCU ACC UGU UCC AUG GCC ATT (sense) and UGG CCA UGG AAC
AGG UAG CTT.
-TrCP siRNA was mixed with 800 ng of carrier DNA (pcDNA) and transfected into the 293 cells in 2 ml of culturing medium. 24 h later, the same transfection was performed to achieve high efficiency gene suppression. 24 h following the second siRNA transfection, DNA expression vectors encoding p100 and the other indicated proteins were transfected into the cells. Protein extracts and RNA were prepared at 24-30 h after the DNA transfection. The efficiency of
-TrCP gene suppression was monitored by RT-PCR.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-TrCP Is Required for NIK-induced Processing of p100--
As
described earlier (15), the inducible processing of p100 is
associated with its ubiquitination, although it remains unclear whether
this is an essential step in p100 processing. Additionally the
ubiquitin ligase regulating p100 ubiquitination remains to be
identified. We investigated the role of
TrCP in the processing of
p100 using siRNA-mediated gene suppression. As expected from various
other studies (22-24), the
-TrCP siRNA efficiently depleted the
mRNA of
TrCP but not that of a control gene,
glyceraldehyde-3-phosphate dehydrogenase, as detected by the sensitive
RT-PCR analysis (Fig. 1A).
More importantly the
-TrCP suppression led to almost complete blockade of NIK-induced p100 processing. This effect was specific since
the processing of p100 was not affected in cells transfected with the
control GFP siRNA (Fig. 1B, lanes 5-8).
Furthermore the
-TrCP RNAi was also able to inhibit NIK-induced
processing of endogenous p100 (Fig. 1C). These results
provide genetic evidence for an essential role of
-TrCP in the
inducible processing of p100.

View larger version (42K):
[in a new window]
Fig. 1.
-TrCP is an essential factor
for inducible processing of p100 and proteolysis of
I
B
. A, RT-PCR
analysis showing the specific depletion of
-TrCP mRNA in cells
transfected with
-TrCP siRNA. 293 cells were either mock-transfected
with the carrier DNA pcDNA (lane 1) or transfected with
-TrCP siRNA (lane 2) as described under "Materials and
Methods." 24 h after the second transfection, RNA was isolated
from the transfectants and subjected to RT-PCR assays using specific
primers for
-TrCP or control glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). B, suppression of
-TrCP
expression results in blockade of NIK-induced p100 processing. 293 cells were either mock-transfected (lanes 1, 2,
5, and 6) or transfected with siRNA for
-TrCP
(lanes 3 and 4) or GFP (lanes 7 and
8). 24 h after the second transfection, the cells were
then transfected with cDNA expression vectors indicated
below the panels (400 ng for p100 and 300 ng for NIK). The
processing of p100 was analyzed by immunoblotting using anti-p100
24 h after the DNA transfection. C,
-TrCP RNAi also
inhibits the processing of endogenous p100. The transfections were
performed as described in B except for the lack of exogenous
p100. Additionally, to detect the endogenous p100, more cell extracts
(~80 µg) were used in the immunoblotting assay. ns
indicates nonspecific protein bands. D, suppression of
-TrCP expression results in blockade of I
B
degradation. The
cells were transfected as described in B (400 ng for
HA-I
B
and 200 ng for IKK
SS/EE) and subjected to immunoblotting
assays to detect IKK
SS/EE-induced I
B
degradation using the
anti-HA antibody. NT, mock-transfected.
-TrCP is essential for proteolysis of I
B
. For these studies,
we expressed HA-tagged I
B
with a constitutively activated form of
IKK
(IKK
SS/EE). IKK
SS/EE efficiently induced degradation of
I
B
(Fig. 1D, lane 2); however, the
inducible degradation of I
B
was completely blocked in cells
transfected with the
-TrCP siRNA (lane 4).
-TrCP Is Required for NIK-induced Ubiquitination of
p100--
We next examined whether
-TrCP is required for the
ubiquitination of p100. When expressed in 293 cells, NIK efficiently
induced polyubiquitination of p100 as evidenced by the formation of
ubiquitin-conjugated heterogeneous p100 adducts (Fig.
2A, lane 2).
Remarkably the p100 polyubiquitination was largely abrogated when
-TrCP gene expression was suppressed by RNAi (lane 4).
Moreover the RNAi-mediated inhibition of p100 ubiquitination was
associated with the marked diminishment of NIK-induced p100 processing
(Fig. 2B, lane 4). To further confirm the
inhibitory effect of
-TrCP siRNA was specifically caused by the loss
of
-TrCP, functional rescue was performed by transfecting the
siRNA-treated cells with a
-TrCP mutant harboring sense mutations in
the siRNA targeting site (RNAi-resistant
-TrCP or
TrCPiR). As shown in Fig. 2, both the ubiquitination and
the processing of p100 were efficiently restored in cells expressing
the RNAi-resistant form of
-TrCP (Fig. 2, A and
B, lane 6). Thus,
-TrCP is an essential component for regulating the ubiquitination of p100.

View larger version (27K):
[in a new window]
Fig. 2.
-TrCP is an essential factor
for inducible ubiquitination of p100. A and
B, 293 cells were either mock-transfected or transfected
with
-TrCP siRNA as described in Fig. 1. The cells were then
transfected with expression vectors encoding p100 (400 ng) and
HA-tagged ubiquitin (400 ng) together with either the pcDNA vector
or an RNAi-resistant form of
-TrCP (
-TrCPiR, 400 ng).
Cell lysates were subjected to coIP (A) and
immunoblotting (B) to detect p100 ubiquitin conjugation and
processing, respectively. ub, ubiquitin.
-TrCP--
We then examined
whether
-TrCP physically interacts with p100 by coIP assays. When
expressed in 293 cells,
-TrCP only weakly interacted with p100 in
the absence of the processing-inducing kinase NIK (Fig.
3A, top panel,
lane 1). However, in the presence of NIK,
-TrCP formed a
stable complex with p100 and was readily coprecipitated by the p100
antibody (lane 2). In contrast, a catalytically inactive NIK
mutant (NIK(K429A/K430A)) failed to induce the binding of
-TrCP to p100. This functional difference was not due to variation in protein expression since similar amounts of NIK and NIK mutant were
detected by immunoblotting in the cell lysates (Fig. 3A, middle panel). The levels of
-TrCP (middle
panel) and p100 (bottom panel) were also comparable in
the different cell transfectants. Furthermore the NIK-induced
p100/
-TrCP interaction was tightly associated with the induction of
p100 processing (bottom panel). Finally the molecular
interaction between
-TrCP and p100 appeared to be strong since
-TrCP also formed a stable complex with endogenous p100 in the
presence of NIK (Fig. 3B, lane 3).

View larger version (29K):
[in a new window]
Fig. 3.
NIK induces physical interaction of
-TrCP with p100, which requires the phosphorylation
site of p100. A, 293 cells were transfected using
DEAE-dextran with expression vectors encoding p100 (0.7 µg) and
HA-tagged
-TrCP (1 µg) together with either an empty vector (
),
HA-tagged NIK (0.5 µg), or a catalytically inactive NIK mutant
(NIK Mut). Cell lysates were subjected to
immunoprecipitation using anti-p100, and the coprecipitated
-TrCP
was detected by immunoblotting using anti-HA (top panel). In
the middle and bottom panels, the cell lysates
were directly subjected to immunoblotting to monitor the expression
levels of HA-tagged NIK, NIK mutant, and
-TrCP (middle
panel) as well as of the p100 and processing product p52
(bottom panel). ns indicates a nonspecific
protein band. B, 293 cells were transfected with HA-tagged
-TrCP either alone or together with NIK. Endogenous p100 was
isolated by IP using anti-p100 followed by immunoblotting to detect
associated
-TrCP. C, 293 cells were transfected with the
indicated expression vectors and subjected to coIP (top
panel) and immunoblotting (middle and bottom
panels) assays as described in A. The expression level
of NIK was similar to that shown in the middle panel of
A (data not shown). P100SS/AA harbors serine to alanine
mutations in its phosphorylation site.
-TrCP recognition. This idea was tested by
performing the coIP assays using a p100 mutant (p100SS/AA, see Ref. 15)
harboring serine to alanine mutations at its phosphorylation site. As
expected, the p100SS/AA did not respond to NIK for processing (Fig.
3C, bottom panel, lane 5). More
importantly this p100 mutant also failed to interact with
-TrCP
(top panel, lane 5) or become polyubiquitinated
(data not shown and Ref. 15) in NIK-expressing cells. These findings
strongly suggest the direct involvement of
-TrCP in catalyzing the
polyubiquitination of p100.
-TrCP--
We have previously shown that a DD located in the
C-terminal region of p100 functions to suppress the constitutive
processing of p100. Mutant forms of p100 harboring a DD deletion
(p100
DD) or C-terminal truncations undergo constitutive processing
(Ref. 15 and Fig. 4B). It has
remained unclear how the constitutive processing of p100 is mediated.
One possibility we considered was that the constitutively processed
p100 mutants bind to
-TrCP independently of NIK. This idea was
tested by coIP assays using
-TrCP and p100
DD or a p100 C-terminal
truncation mutant lacking the DD and additional C-terminal sequences
(p100-(1-454)). To our surprise, neither p100
DD nor
p100-(1-454) was able to bind
-TrCP (Fig. 4A,
lanes 4 and 6) even when NIK was expressed in the
cells (lanes 5 and 7). Consistently NIK did not
enhance the constitutive processing of the p100 mutants (Fig.
4B, lanes 4 and 6) but markedly
induced the processing of the wild type NIK (lane 2). This
result prompted us to determine whether
-TrCP is required for p100
constitutive processing. In sharp contrast to the results obtained with
the inducible processing of p100, the constitutive processing of
p100-(1-454) was not affected by RNAi-mediated
-TrCP gene
suppression (Fig. 4C, lanes 5 and 6). Similar results were obtained with the p100
DD (data not shown). Thus, the constitutive processing of p100 appears to be independent of
-TrCP.

View larger version (27K):
[in a new window]
Fig. 4.
-TrCP is dispensable for the
constitutive processing of p100 mutants lacking its C-terminal
processing-inhibitory domain. A,
-TrCP does not bind
to p100 mutants lacking the DD or the entire C-terminal sequences. 293 cells were transfected with HA-tagged
-TrCP together with the
indicated p100 or its mutants. CoIP was performed as described in Fig.
3 to detect the binding of
-TrCP to the p100 proteins (upper
panel). The level of
-TrCP expression was analyzed by
immunoblotting using anti-HA (lower panel). The expression
levels of different p100 proteins were comparable (see B).
B, immunoblotting analysis of the p100 proteins using the
cell lysates from A. C, 293 cells were either
mock-transfected (lanes 1-4) or transfected with
-TrCP
siRNA (lanes 5 and 6) followed by transfection of
cDNA expression vectors encoding wild type p100 (wt) or
a p100 mutant lacking its C-terminal portion (1-454) either
in the absence (
) or presence (+) of NIK. Processing of the p100
proteins was analyzed by immunoblotting using anti-p100.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
b2 gene product, p100, to
generate p52 is an important step of NF-
B regulation, which is
specifically involved in the development and maturation of secondary
lymphoid organs. Emerging evidence suggests that the mechanism of p100 processing differs from that regulating signal-induced degradation of
the labile NF-
B inhibitor I
B
. Our previous studies using the
alymphoplasia mice clearly demonstrate an essential role for the NIK
kinase in regulating p100 processing in lymphoid organs (15). On the
other hand, NIK is not required for cytokine-stimulated degradation of
I
B
or the nuclear translocation of the prototypical form of
NF-
B (RelA/p50) (25, 26). Further studies reveal that IKK
, which
is critical for the canonical NF-
B signaling pathway, is dispensable
for NIK-induced p100 processing, while IKK
is an essential component
of the NIK/p100 pathway (16). We have now extended the previous studies
by investigating the mechanism of p100 polyubiquitination and its role
in p100 processing. Using the powerful siRNA-mediated gene suppression
technique, we have provided genetic evidence for the critical
involvement of
-TrCP in p100 polyubiquitination (Fig.
2A). Furthermore inhibition of p100 ubiquitination in
-TrCP-deficient cells results in blockade of the inducible
processing of p100 (Figs. 1B and 2B). These
findings suggest that polyubiquitination of p100 is mediated through
the
-TrCP-specific ubiquitin ligase and serves as an essential step in the inducible p100 processing.
-TrCP mutant suggest that
-TrCP also participates in ubiquitination of several other proteins,
including I
B
, p105, human immunodeficiency virus Vpu, and
-catenin (11). With the siRNA technique, we can now determine whether
-TrCP is essential for the ubiquitination and proteolysis of
each of the putative target proteins. Our RNAi studies have confirmed
the essential role of
-TrCP in IKK
-induced degradation of
I
B
(Fig. 1D) and p105 (data not shown). A conserved
site for
-TrCP binding, containing phosphorylated serines and
flanking residues, has been found in the various putative
-TrCP
targets (Ref. 11; see Fig. 5). The
-TrCP binding site in p100 contains most, although not all, of the
conserved amino acid residues found in the other proteins (Fig. 5).
Mutation of the two conserved serines to alanines within this site in
p100 completely abolished its ability to bind
-TrCP (Fig.
3C). Interestingly, in addition to the C-terminal
phosphorylation site, the DD of p100 is required for its interaction
with
-TrCP (Fig. 4A). Consistent with this finding, the
p100 mutant lacking the DD is defective in ubiquitination (15).

View larger version (47K):
[in a new window]
Fig. 5.
Binding sequences of
-TrCP in different human proteins.
stands for hydrophobic amino acids.
-cat,
-catenin.
-TrCP. Consistently these mutants do
not physically interact with
-TrCP. This finding suggests two
possibilities regarding how the constitutive processing of p100 is
regulated. First, the N-terminal region of p100 may interact with
another yet to be identified ubiquitin ligase, which targets p100
mutants for constitutive ubiquitination and proteasome recruitment.
Second, the constitutive processing of p100 may not involve
ubiquitination. In favor of the second possibility, we have been unable
to detect polyubiquitination of the constitutively processed forms of
p100 using the in vivo ubiquitination method (Ref. 15 and
data not shown). Although these results cannot exclude the possibility
for involvement of weak ubiquitination in the constitutive processing
of p100 mutants, it nevertheless suggests that strong
polyubiquitination is specifically required for the inducible
processing of p100.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
To whom correspondence should be addressed: Dept. of Microbiology
and Immunology, Pennsylvania State University College of Medicine, 500 University Dr., Hershey, PA 17033. Tel.: 717-531-4164; Fax:
717-531-6522; E-mail: sxs70@psu.edu.
![]()
ABBREVIATIONS
B kinase;
-TrCP,
-transducin repeat-containing protein;
DD, death domain;
PID, processing-inhibitory domain;
NIK, NF-
B-inducing kinase;
RNAi, RNA interference;
siRNA, small interfering RNA;
GFP, green fluorescent
protein;
IB, immunoblotting;
coIP, coimmunoprecipitation;
IP, immunoprecipitation;
-TrCPiR, RNAi-resistant
-TrCP;
HA, hemagglutinin;
RT, reverse transcription;
RIPA, radioimmune
precipitation buffer;
SCF, Skp1-Cullin-1/Cdc53-F box
protein.
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
1.
Silverman, N.,
and Maniatis, T.
(2001)
Genes Dev.
15,
2321-2342 2.
Gilmore, T. D.,
Koedood, M.,
Piffat, K. A.,
and White, D. W.
(1996)
Oncogene
13,
1367-1378[Medline]
[Order article via Infotrieve]
3.
Barkett, M.,
and Gilmore, T. D.
(1999)
Oncogene
69,
6910-6924
4.
Karin, M.,
and Lin, A.
(2002)
Nat. Immunol.
3,
221-227[CrossRef][Medline]
[Order article via Infotrieve]
5.
Rayet, B.,
and Gelinas, C.
(1999)
Oncogene
18,
6938-6947[CrossRef][Medline]
[Order article via Infotrieve]
6.
Baldwin, A. S.
(2001)
J. Clin. Investig.
107,
241-246[CrossRef][Medline]
[Order article via Infotrieve]
7.
Siebenlist, U.,
Franzoso, G.,
and Brown, K.
(1994)
Annu. Rev. Cell Biol.
10,
405-455[CrossRef][Medline]
[Order article via Infotrieve]
8.
Baldwin, A. S., Jr.
(1996)
Annu. Rev. Immunol.
14,
649-683[CrossRef][Medline]
[Order article via Infotrieve]
9.
Brown, K.,
Gerstberger, S.,
Carlson, L.,
Franzoso, G.,
and Siebenlist, U.
(1995)
Science
267,
1485-1488 10.
Brockman, J. A.,
Scherer, D. C.,
McKinsey, T. A.,
Hall, S. M., Qi, X.,
Lee, W. Y.,
and Ballard, D. A.
(1995)
Mol. Cell. Biol.
15,
2809-2818[Abstract]
11.
Karin, M.,
and Ben-Neriah, Y.
(2000)
Annu. Rev. Immunol.
18,
621-663[CrossRef][Medline]
[Order article via Infotrieve]
12.
Fan, C. M.,
and Maniatis, T.
(1991)
Nature
354,
395-398[CrossRef][Medline]
[Order article via Infotrieve]
13.
Rice, N. R.,
MacKichan, M. L.,
and Israel, A.
(1992)
Cell
71,
243-253[CrossRef][Medline]
[Order article via Infotrieve]
14.
Mercurio, F.,
DiDonato, J. A.,
Rosette, C.,
and Karin, M.
(1993)
Genes Dev.
7,
705-718 15.
Xiao, G.,
Harhaj, E. W.,
and Sun, S. C.
(2001)
Mol. Cell.
7,
401-409[CrossRef][Medline]
[Order article via Infotrieve]
16.
Senftleben, U.,
Cao, Y.,
Xiao, G.,
Kraehn, G.,
Greten, F.,
Chen, Y., Hu, Y.,
Fong, A.,
Sun, S.-C.,
and Karin, M.
(2001)
Science
293,
1495-1499 17.
Xiao, G.,
Cvijic, M. E.,
Fong, A.,
Harhaj, E. W.,
Uhlik, M. T.,
Waterfield, M.,
and Sun, S. C.
(2001)
EMBO J.
20,
6805-6815[CrossRef][Medline]
[Order article via Infotrieve]
18.
Harhaj, E. W.,
and Sun, S.-C.
(1999)
J. Biol. Chem.
274,
22911-22914 19.
Sun, S.-C.,
Ganchi, P. A.,
Beraud, C.,
Ballard, D. W.,
and Greene, W. C.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
1346-1350 20.
Holbrook, N.,
Gulino, A.,
and Ruscetti, F.
(1987)
Virology
157,
211-219[CrossRef][Medline]
[Order article via Infotrieve]
21.
Uhlik, M.,
Good, L.,
Xiao, G.,
Harhaj, E. W.,
Zandi, E.,
Karin, M.,
and Sun, S.-C.
(1998)
J. Biol. Chem.
273,
21132-21136 22.
Caplen, N. J.
(2002)
Trends Biotechnol.
20,
49-51[CrossRef][Medline]
[Order article via Infotrieve]
23.
Harborth, J.,
Elbashir, S. M.,
Bechert, K.,
Tuschl, T.,
and Weber, K.
(2001)
J. Cell Sci.
114,
4557-4565[Medline]
[Order article via Infotrieve]
24.
Luo, X.,
Tang, Z.,
Rizo, J.,
and Yu, H.
(2002)
Mol. Cell
9,
59-71[CrossRef][Medline]
[Order article via Infotrieve]
25.
Shinkura, R.,
Kitada, K.,
Matsuda, F.,
Tashiro, K.,
Ikuta, K.,
Suzuki, M.,
Kogishi, K.,
Serikawa, T.,
and Honjo, T.
(1999)
Nat. Genet.
22,
74-77[CrossRef][Medline]
[Order article via Infotrieve]
26.
Yin, L., Wu, L.,
Wesche, H.,
Arthur, C. D.,
White, J. M.,
Goeddel, D. V.,
and Schreiber, R. D.
(2001)
Science
291,
2162-2165
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
X. L. Ang, D. P. Seeburg, M. Sheng, and J. W. Harper Regulation of Postsynaptic RapGAP SPAR by Polo-like Kinase 2 and the SCF{beta}-TRCP Ubiquitin Ligase in Hippocampal Neurons J. Biol. Chem., October 24, 2008; 283(43): 29424 - 29432. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Fusco, O. V. Savinova, R. Talwar, J. D. Kearns, A. Hoffmann, and G. Ghosh Stabilization of RelB Requires Multidomain Interactions with p100/p52 J. Biol. Chem., May 2, 2008; 283(18): 12324 - 12332. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Tucker, K. O'Donnell, M. Fuchsberger, A. A. Hilton, D. Metcalf, K. Greig, N. A. Sims, J. M. Quinn, W. S. Alexander, D. J. Hilton, et al. A Novel Mutation in the Nfkb2 Gene Generates an NF-{kappa}B2 "Super Repressor" J. Immunol., December 1, 2007; 179(11): 7514 - 7522. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-G. Deng, S.-T. Tang, H.-P. Tseng, and K. K. Wu Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding Blood, July 15, 2006; 108(2): 518 - 524. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tempe, M. Casas, S. Karaz, M.-F. Blanchet-Tournier, and J.-P. Concordet Multisite Protein Kinase A and Glycogen Synthase Kinase 3{beta} Phosphorylation Leads to Gli3 Ubiquitination by SCF{beta}TrCP. Mol. Cell. Biol., June 1, 2006; 26(11): 4316 - 4326. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Pan, C. B. Bai, A. L. Joyner, and B. Wang Sonic hedgehog Signaling Regulates Gli2 Transcriptional Activity by Suppressing Its Processing and Degradation. Mol. Cell. Biol., May 1, 2006; 26(9): 3365 - 3377. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Wang and Y. Li Evidence for the direct involvement of {beta}TrCP in Gli3 protein processing PNAS, January 3, 2006; 103(1): 33 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Qing, Z. Qu, and G. Xiao Stabilization of Basally Translated NF-{kappa}B-inducing Kinase (NIK) Protein Functions as a Molecular Switch of Processing of NF-{kappa}B2 p100 J. Biol. Chem., December 9, 2005; 280(49): 40578 - 40582. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Richardson and W. Zundel The Emerging Role of the COP9 Signalosome in Cancer Mol. Cancer Res., December 1, 2005; 3(12): 645 - 653. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wan, J. Huang, N. C. Jhala, E. M. Tytler, L. Yang, S. M. Vickers, Y. Tang, C. Lu, N. Wang, and X. Cao SCF{beta}-TrCP1 Controls Smad4 Protein Stability in Pancreatic Cancer Cells Am. J. Pathol., May 1, 2005; 166(5): 1379 - 1392. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Qing and G. Xiao Essential Role of I{kappa}B Kinase {alpha} in the Constitutive Processing of NF-{kappa}B2 p100 J. Biol. Chem., March 18, 2005; 280(11): 9765 - 9768. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hu and N. H. Colburn Histone Deacetylase Inhibition Down-Regulates Cyclin D1 Transcription by Inhibiting Nuclear Factor-{kappa}B/p65 DNA Binding Mol. Cancer Res., February 1, 2005; 3(2): 100 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Qing, Z. Qu, and G. Xiao Regulation of NF-{kappa}B2 p100 Processing by Its cis-Acting Domain J. Biol. Chem., January 7, 2005; 280(1): 18 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Shcherbik, Y. Kee, N. Lyon, J. M. Huibregtse, and D. S. Haines A Single PXY Motif Located within the Carboxyl Terminus of Spt23p and Mga2p Mediates a Physical and Functional Interaction with Ubiquitin Ligase Rsp5p J. Biol. Chem., December 17, 2004; 279(51): 53892 - 53898. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Qu, G. Qing, A. Rabson, and G. Xiao Tax Deregulation of NF-{kappa}B2 p100 Processing Involves Both {beta}-TrCP-dependent and -independent Mechanisms J. Biol. Chem., October 22, 2004; 279(43): 44563 - 44572. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kudo, D. Guardavaccaro, P. G. Santamaria, R. Koyama-Nasu, E. Latres, R. Bronson, L. Yamasaki, and M. Pagano Role of F-Box Protein {beta}Trcp1 in Mammary Gland Development and Tumorigenesis Mol. Cell. Biol., September 15, 2004; 24(18): 8184 - 8194. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Hayden and S. Ghosh Signaling to NF-{kappa}B Genes & Dev., September 15, 2004; 18(18): 2195 - 2224. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-H. Hu, X.-M. Mo, W. M. Walters, R. Brambilla, and J. R. Bethea TNAP, a Novel Repressor of NF-{kappa}B-inducing Kinase, Suppresses NF-{kappa}B Activation J. Biol. Chem., August 20, 2004; 279(34): 35975 - 35983. [Abstract] [Full Text] [PDF] |
||||
![]() |
|